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Activating Immunity to Fight a Foe — A New Path
Richard S. Hotchkiss, M.D., and Steven M. Opal, M.D.
The discovery of antibiotics is perhaps the single
most important advance in medicine in the past
century. However, the emergence of multidrugresistant pathogens has rendered many antibiotics ineffective and is fueling a crisis: a dramatically increased incidence of infections refractory
to treatment, resulting in more than 35,000 deaths
in the United States in 2019. Fortuitously, knowledge of cellular mechanisms of immunity, including those undergirded by subclasses of T cells,
is also growing.1 Recent reports by Amezcua
Vesely et al.1 and Zander et al.2 augment this
knowledge and provide support for the development of drugs that boost immunity in patients
with life-threatening infections.3,4
Death in the context of sepsis has until relatively recently been considered to be the result of
hyperinflammation mediated by cytokine storm,
but subsequent work revealed this to be an inadequate explanation.3,4 Advances in supportive therapies have markedly decreased deaths during the
early phases of septic shock; a protracted immunosuppression after the initial inflammatory
phase occurs in the large majority of surviving
patients.3,4 Multiple mechanisms drive immunosuppression, including apoptosis-induced lymphocyte depletion, increased numbers of myeloidderived suppressor cells and regulatory T cells,
and T-cell exhaustion. The effect of immunosuppression is manifested by the incidence of new
secondary infections, often due to weakly virulent pathogens, that occur in 30 to 40% of patients with protracted sepsis.3,4 Further evidence
of the critical role of host immunity in surviving
sepsis is suggested by the characteristics of patients who die: older patients, in whom immuno
senescence is known to be prevalent, and patients who have alcoholism, are malnourished,
or have cancer or serious coexisting conditions
that impair the immune system. The reactivation
of multiple latent viruses that occurs in 50% of
patients with protracted sepsis further illustrates
their severe immunosuppression.4
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Mucosal-associated invariant T (MAIT) cells
and γδ T cells are innate-like lymphocytes that
line bronchial mucosa and respond rapidly to
pathogen invasion by secreting cytokines essential for microbial killing: interferon-γ and interleukin-17. Amezcua Vesely et al. have added CD4
tissue-resident memory T (CD4 TRM) cells to this
group: they found that these cells are present in
the lung and are derived from effector TH17 cells
(which secrete interleukin-17) and that they
eliminate bacteria, including carbapenem-resistant Klebsiella pneumoniae, in mouse models of
Figure 1 (facing page). New Therapeutic Paradigm
in Infectious Disease.
The current general strategy to treat infectious disease
(Panel A) involves the rapid administration of antimicrobial drugs that target the pathogens. In the future
(Panel B), immunoadjuvants that activate early-responding immune effector cells (green arrows) or that alleviate
immunosuppressive mechanisms (red lines) are likely
to be used in addition to antimicrobial agents. Mucosal-associated invariant T (MAIT) cells and γδ T cells
respond rapidly to eliminate invading pathogens. Recent studies identified additional new classes of earlyresponding immune effector cells, including CD4 and
CD8 tissue-resident memory T (CD4 TRM and CD8 TRM)
cells that play key roles in host defense.1,2 T-cell exhaustion, myeloid-derived suppressor cells (MDSCs), and
regulatory T (Treg) cells are important sources of immunosuppression in patients with protracted infections,
including sepsis. Interleukin-7, anti–programmed death 1
(PD-1), interferon-γ, and granulocyte–macrophage colonystimulating factor (GM-CSF) are immunoadjuvants
that have been used on a compassionate basis in patients with life-threatening bacterial, fungal, and viral
infections and in small clinical trials involving patients
with sepsis (see the Supplementary Appendix, available
with the full text of this article at NEJM.org). Interleukin-7 and anti–PD-1 activate γδ T cells and MAIT cells.
Interleukin-7 sustains CD4 TRM cells. Anti–PD-1 blocks
PD-1 to reverse T-cell exhaustion. APC denotes antigenpresenting cell, IL-7R interleukin-7 receptor, IL-12R interleukin-12 receptor, MHC-I major histocompatibility
complex class I, MHC-II major histocompatibility complex class II, MR1 major histocompatibility complex
class I–related protein, and TCR T-cell receptor.
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infection.1 They further determined that inter- a new supportive role for CD4 T cells that proleukin-7 was required for maintenance of these duce interleukin-21: they stimulate the generaCD4 TRM cells in the lung. Zander et al. reported tion of a subset of CD8 T cells that eliminated
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virus-infected cells in a mouse model of latent
viral infection.
These studies have implications for the development of experimental immunoadjuvant therapies (Fig. 1). In the past several years, phase 1
and 2 trials of granulocyte–macrophage colonystimulating factor, interferon-γ, anti–programmed
death 1 (PD-1), anti–programmed death ligand 1
(PD-L1), and interleukin-7 were conducted in
patients with sepsis. Although the trials were
small, the results suggested that the drugs had
satisfactory safety profiles, did not induce cytokine storm, and improved indexes of patient
immunity.3-5 Furthermore, there are increasing
numbers of case reports documenting clinical
improvements in patients receiving immunoadjuvant agents for the treatment of life-threatening infection by pathogens, including JC virus
(the causative agent in progressive multifocal
leukoencephalopathy), hepatitis C virus, Staphylococcus aureus, disseminated candidiasis, and mucormycosis (see the Supplementary Appendix).
Several of these immunoadjuvants activate rapidly
responding immune cells, including CD4 TRM
cells, MAIT cells, and γδ T cells. Collectively,
these studies suggest that immunoadjuvant therapies could be tested experimentally as treatment for otherwise intractable infections, including those occurring in the context of sepsis.
Until recently, most trials that studied ways
to boost immunity in patients with sepsis targeted neutrophils and monocytes but not T cells.
The immune system is like an orchestra that
functions best when all components work harmoniously; by this analogy, the CD4 helper T cell is
the conductor. The importance of targeting T cells
for an effective immune response is demonstrated in oncology: checkpoint inhibitors that
reverse T-cell exhaustion are the current oncologic “superstars” and are included in most ongoing immunotherapy trials. The remarkable
power of T cells is underscored by approval of
anti–PD-1 and anti–PD-L1 drugs to treat more
than 10 highly diverse types of tumor. Interleukin-7, which is currently being tested in several
oncology trials, activates not only CD4 and CD8
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T cells but also MAIT cells and γδ T cells. We
predict that combination drug therapies will ultimately become the standard for sepsis as well.
What needs to be done? There are more than
1700 immunotherapy trials under way in oncology, whereas almost no trials involving patients
with sepsis are under way. Most important,
pharmaceutical and National Institutes of Health
leaders need vision and courage to support trials
that boost host immunity in infectious diseases,
including sepsis. The failures of drugs that were
tested in previous sepsis trials, almost all of
which were designed to block cytokine-mediated
hyperinflammation, probably rested on misconceptions of the mechanisms underlying the disorder. Similar intense skepticism regarding immunotherapy pervaded the oncology field until
the dramatic success of checkpoint inhibitors.
Ideal candidates for immunoadjuvant therapies
are patients with hospital-acquired infections,
infections with multidrug-resistant bacteria, or
fungal infections. These patients almost always
have immunosuppression, and mortality among
such patients is high. Should immunotherapy
prove to be an effective treatment, it could serve
as a weapon against increasingly lethal foes.
Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.
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